StockNews.com Begins Coverage on Eagle Pharmaceuticals (NASDAQ:EGRX)

Investment analysts at StockNews.com started coverage on shares of Eagle Pharmaceuticals (NASDAQ:EGRX) in a research note issued to investors on Monday. The firm set a “hold” rating on the specialty pharmaceutical company’s stock.

Eagle Pharmaceuticals Stock Performance

Eagle Pharmaceuticals stock opened at $1.17 on Monday. The stock’s 50 day simple moving average is $0.72 and its two-hundred day simple moving average is $1.83. Eagle Pharmaceuticals has a 12 month low of $0.00 and a 12 month high of $6.81.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in EGRX. RBF Capital LLC boosted its stake in shares of Eagle Pharmaceuticals by 11.7% during the 3rd quarter. RBF Capital LLC now owns 143,078 shares of the specialty pharmaceutical company’s stock worth $534,000 after acquiring an additional 14,991 shares in the last quarter. Jacobs Levy Equity Management Inc. purchased a new position in shares of Eagle Pharmaceuticals in the 3rd quarter valued at about $453,000. DGS Capital Management LLC raised its holdings in Eagle Pharmaceuticals by 44.9% in the 3rd quarter. DGS Capital Management LLC now owns 71,728 shares of the specialty pharmaceutical company’s stock worth $268,000 after purchasing an additional 22,239 shares during the period. Jane Street Group LLC purchased a new position in Eagle Pharmaceuticals during the third quarter worth approximately $96,000. Finally, Creative Planning acquired a new stake in Eagle Pharmaceuticals in the third quarter valued at approximately $59,000. Hedge funds and other institutional investors own 85.36% of the company’s stock.

Eagle Pharmaceuticals Company Profile

Eagle Pharmaceuticals, Inc, a pharmaceutical company, focuses on developing and commercializing product candidates to treat diseases of the central nervous system or metabolic critical care, and oncology in the United States. The company offers Ryanodex for malignant hyperthermia; and Belrapzo and Bendeka for chronic lymphocytic leukemia and indolent B-cell non-Hodgkin’s lymphoma.